A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 1
Abstract
Background: Colorectal cancer is one major health problem and cancer-related cause of death in cancer patients in countries such as Iran where the most cases are diagnosed in advanced stages. Objectives: To evaluate the incidence and severity of toxic effects in colorectal cancer patients who have been treated with two different schedules of combination of oxaliplatin and bolus/infusional 5-fluorouracil with leucovorin (FOLFOX) and to compare them. Methods: Medical records of 458 patients with colorectal cancer treated with FOLFOX 4 and modified FOLFOX 6 regimen between 2005 and 2014 were reviewed. Data from 96 eligible patients were analyzed. Fifty-six patients (58.3%) received FOLFOX 4 and 40 patients (41.7%) received modified FOLFOX 6. Results: The study included 96 patients, 39 of whom were males (40.6%) and 57 of whom were females (59.4%). The median age was 62 years (range: 38 - 87 years). The follow up duration was between 16 - 109 months with a median of 62 months. There was a statistically significant incidence rate of grade 1 toxicity of diarrhea as gastrointestinal (GI) toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.034), but there was not a statistically significant incidence rate of grade 1 toxicity of stomatitis as GI toxicity between the two regimens (P = 0.27).We observed a highly statistically significant incidence rate of grade 1 toxicity of neutropenia as hematologic toxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P < 0.001), but we did not observe any statistically significant differences of grade 1 of thrombocytopenia as hematologic toxicity between the two regimens (P = 0.063). There was a statistically significant incidence rate of grade 1 neurotoxicity between FOLFOX 4 and modified FOLFOX 6 as the two regimens (P = 0.017). Conclusions: We showed that in colorectal cancer patients treated with modified FOLFOX6. Some of hematological and nonhematological complications were more than FOLFOX4 and they can be concerned.
Applying Bioinformatic Tools for Modeling and Modifying Type II <i>E. coli</i> l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia
Background Asparginase is known to be one of the most important bedrocks of acute lymphoblastic leukemia (ALL) treatment in almost all pediatric regimens in treatment protocols. <...
Application of Cold Atmospheric Plasma (CAP) in Cancer Therapy: A Review
Background Recently the use of cold atmospheric plasma (CAP) for the treatment of cancers called “Plasma Oncology” has gained promising results. The developments have raised the h...
Clinicopathology Figures and Survival of Non-Hodgkin’s Lymphoma in Iran
Background: Non-Hodgkin’s lymphoma (NHL) is the fifth most frequently diagnosed cancer whose incidence has risen by at least 100 percent over the past five decades especially in theWest. Objectives: The aim of this study...
Oncoplastic Breast Surgery; Is It Possible to Perform It in Every Medical Center?
No Abstract
A Comparative Study of FIGO 1988 Versus 2009 Staging for Endometrial Carcinoma
Objectives: The aim of this study was to investigate the benefits of the newly revised “The international federation of gynecology and obstetrics (FIGO), 2009” sytem and whether there was a difference in new system compa...